Search
Letermovir
go.drugbank.com/drugs/DB12070ApprovedInvestigationalLetermovir recieved approval from the FDA on November 8th, 2017 for use in prophylaxis of cytomegalovirus (CMV) infection in allogeneic hematopoietic stem cell transplant patients. It is the first of a new class of CMV anti-infectives ca...
Idursulfase
go.drugbank.com/drugs/DB01271ApprovedInvestigationalIdursulfase is produced by recombinant DNA technology in a human cell line. … The enzyme contains eight asparagine-linked glycosylation sites occupied by complex oligosaccharide structures.
Corticotropin
go.drugbank.com/drugs/DB01285ApprovedInvestigationalVet approvedCorticotropin (ACTH or adrenocorticotropic hormone) is a polypeptide hormone produced and secreted by the pituitary gland. It is an important player in the hypothalamic-pituitary-adrenal axis.
Tolazamide
go.drugbank.com/drugs/DB00839ApprovedA sulphonylurea hypoglycemic agent with actions and uses similar to those of chlorpropamide.
Nalbuphine
go.drugbank.com/drugs/DB00844ApprovedInvestigationalIt appears to be an agonist at kappa opioid receptors and an antagonist or partial agonist at mu opioid receptors.
Beremagene geperpavec
go.drugbank.com/drugs/DB17831ApprovedInvestigationalDeveloped by Krystal Biotech, it was first approved by the FDA on May 19, 2023, for the treatment of wounds associated with dystrophic epidermolysis bullosa (DEB). … [L46916] DEB is caused by mutations in the _COL7A1_ gene that encodes collagen VII (COL7), a major component of the anchoring fibrils for dermal–epidermal cohesion.
Brigatinib
go.drugbank.com/drugs/DB12267ApprovedInvestigational[A31313] Brigatinib was developed by Ariad Pharmaceuticals, a subsidiary of Takeda Pharmaceutical Company Limited, and FDA-approved on April 28, 2017.[L1026]
Cinchocaine
go.drugbank.com/drugs/DB00527ApprovedVet approvedA local anesthetic of the amide type now generally used for surface anesthesia. It is one of the most potent and toxic of the long-acting local anesthetics and its parenteral use is restricted to spinal anesthesia. (From Martindale, The ...
Rimegepant
go.drugbank.com/drugs/DB12457ApprovedInvestigationalRimegepant is an oral antagonist of the CGRP receptor developed by Biohaven Pharmaceuticals. … [L38814] The current standard of migraine therapy involves abortive treatment with "triptans", such as [sumatriptan], but these medications are contraindicated in patients with pre-existing cerebrovascular
Alirocumab
go.drugbank.com/drugs/DB09302ApprovedInvestigationalAlirocumab is a biopharmaceutical that obtained FDA approval in July 2015 as a second line treatment for high cholesterol in adults whose LDL-cholesterol (LDL-C) is not controlled by the combination of